Carcinoma, Non-Small-Cell Lung
Showing NaN - NaN of 44
Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)
Recruiting
- Solid Tumor
- +11 more
-
Belfast, United Kingdom
- +16 more
Mar 2, 2023
NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)
Recruiting
- Non-Small Cell Lung Cancer
- +14 more
-
Glendale, California
- +12 more
Feb 2, 2023
NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +2 more
-
Duarte, California
- +228 more
Jan 31, 2023
NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Alectnib
- +5 more
-
Chicago, Illinois
- +140 more
Jan 20, 2023
NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Sasanlimab Prefilled syringe
- +5 more
-
Duarte, California
- +96 more
Jan 18, 2023
Tumors, NSCLC Trial in Worldwide (BI 754111, BI 754091)
Active, not recruiting
- Neoplasms
- Carcinoma, Non-Small-Cell Lung
- BI 754111
- BI 754091
-
Miami, Florida
- +14 more
Jan 9, 2023
NSCLC Trial in Worldwide (INC280 (capmatinib))
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- INC280 (capmatinib)
-
Long Beach, California
- +95 more
Dec 29, 2022
NSCLC Trial in Worldwide (Selpercatinib, Placebo)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Selpercatinib
- Placebo
-
Santa Monica, California
- +206 more
Dec 27, 2022
NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +2 more
-
Tuscaloosa, Alabama
- +260 more
Dec 16, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)
Recruiting
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- +9 more
-
Mobile, Alabama
- +194 more
Aug 18, 2022
Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)
Not yet recruiting
- Carcinoma, Non-small-Cell Lung
- Amivantamab
- +3 more
-
Westwood, Kansas
- +47 more
Aug 17, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
Urinary Bladder Tumors, Colorectal Cancer, NSCLC Trial in Worldwide (AZD8853, Zirconium-89 crefmirlimab berdoxam)
Recruiting
- Urinary Bladder Neoplasms
- +2 more
- AZD8853
- Zirconium-89 crefmirlimab berdoxam
-
New Haven, Connecticut
- +14 more
Aug 8, 2022
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Orange, California
- +40 more
Aug 3, 2022
NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- nab-paclitaxel IV
- +2 more
-
San Francisco, California
- +33 more
Jan 24, 2022
NSCLC Trial in Worldwide (LY2875358, Erlotinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- LY2875358
- Erlotinib
-
Herlev, Denmark
- +41 more
Sep 2, 2021
NSCLC Trial in Worldwide (Avelumab, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
-
Tuscaloosa, Alabama
- +259 more
Jul 20, 2020
NSCLC Trial in Worldwide (Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo)
Terminated
- Carcinoma, Non-Small-Cell Lung
- Tislelizumab
- +2 more
-
Los Angeles, California
- +163 more
Jun 26, 2020